Supernus Pharmaceuticals
SUPN
310 hedge funds and large institutions have $2.76B invested in Supernus Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 61 funds opening new positions, 92 increasing their positions, 118 reducing their positions, and 43 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
47% more capital invested
Capital invested by funds: $1.87B → $2.76B (+$882M)
42% more first-time investments, than exits
New positions opened: 61 | Existing positions closed: 43
5% more funds holding
Funds holding: 295 → 310 (+15)
3.33% less ownership
Funds ownership: 106.23% → 102.9% (-3.3%)
22% less repeat investments, than reductions
Existing positions increased: 92 | Existing positions reduced: 118
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$50.5M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$50M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$19.8M |
| 4 |
D.E. Shaw & Co
New York
|
+$15.3M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$13.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$79.6M |
| 2 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$31.6M |
| 3 |
BlackRock
New York
|
-$27M |
| 4 |
ACB
Aristotle Capital Boston
Boston,
Massachusetts
|
-$20.3M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$17M |
SUPN Hedge Fund Activity: Q3 2025 in Review
310 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q3 2025, worth a combined $2.76B — up 47% from $1.87B a quarter earlier.
Buyers outnumbered sellers: 61 funds opened new SUPN positions and 43 closed out — a net gain of 18 holders — while 92 added to existing stakes and 118 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $50.5M. The largest seller was Armistice Capital, cutting an estimated $79.6M.
- 310 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q3 2025, up from 295 in Q2 2025.
- Funds reported $2.76B of Supernus Pharmaceuticals stock for Q3 2025, up 47% quarter-over-quarter.
- 61 funds opened new Supernus Pharmaceuticals positions in Q3 2025 and 43 closed out, a net change of +18 holders.
- The largest Supernus Pharmaceuticals buyer in Q3 2025 was Point72 Asset Management, an estimated $50.5M added.
- The largest Supernus Pharmaceuticals seller in Q3 2025 was Armistice Capital, an estimated $79.6M sold.
Based on aggregated 13F filings for Q3 2025.